QuidelOrtho Sells Rapid Test Unit After 90% Share Price Slump
0h ago|4 min readStandard
Fazen Markets Editorial Desk
Collective editorial team · methodology
quidelorthoprivate-equity
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD 24/5 on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. Vortex HFT is informational software — not investment advice. Past performance does not guarantee future results.
Diagnostic company QuidelOrtho Corporation is pursuing a sale of its Covid-19 rapid testing unit, the Financial Times reported on June 27, 2026. The strategic review follows a catastrophic 90% decline in the company's share price from its peak, when its antigen tests were the first to receive US authorization for Covid-19. Private equity firms are reportedly circling the asset, highlighting a growing trend of financial sponsors targeting undervalued healthcare companies.
The divestiture marks a definitive end to the pandemic-era boom for diagnostic manufacturers. QuidelOrtho was formed in May 2022 through a merger of Quidel Corporation and Ortho Clinical Diagnostics, a transaction valued at approximately $6 billion. The merger was intended to create a diversified diagnostics leader, combining Quidel's rapid test expertise with Ortho's established blood transfusion and clinical laboratory business. The company's rapid antigen tests generated over $3 billion in revenue during 2021.
Current macroeconomic conditions are pressuring highly leveraged companies. With the target federal funds rate at 5.25%-5.50%, financing costs for debt-dependent firms have surged. This environment forces companies with underperforming segments to consider asset sales to shore up their balance sheets. QuidelOrtho's core challenge is the near-total evaporation of demand for Covid-19 testing, which has left its dedicated manufacturing capacity and related operations as a financial drag.
The catalyst for the sale is the sustained erosion of the company's market valuation and the urgent need for strategic repositioning. Management is prioritizing cash flow stability over the volatile revenue stream from a product category that has returned to a negligible baseline. The move signals a retreat from the consumer diagnostics market to refocus on its more stable professional and clinical laboratory segments.
QuidelOrtho's stock price collapsed from a peak of over $180 per share in early 2022 to trade around $18 in recent sessions. This represents a destruction of over $15 billion in market capitalization. The company’s revenue trajectory illustrates the sharp reversal of fortune.
| Period | Rapid Test Revenue | Total Company Revenue |
|---|---|---|
| Fiscal Year 2021 | ~$3.2 Billion | ~$4.5 Billion |
| Fiscal Year 2025 (Est.) | ~$150 Million | ~$3.0 Billion |
The broader diagnostics sector has also faced headwinds, though not as severely. The iShares U.S. Medical Devices ETF (IHI) is down 12% year-to-date, significantly outperforming QuidelOrtho's 45% decline over the same period. The company carries a substantial debt load, with a net debt to EBITDA ratio exceeding 5.0x, well above the industry comfort zone of around 3.0x. This sale is widely viewed as a necessary step to avoid a credit rating downgrade.
The potential sale has immediate second-order effects across the diagnostics and life sciences tools sector. Pure-play competitors like Abbott Laboratories (ABT) and Becton, Dickinson and Company (BDX) may benefit from reduced price competition in the professional diagnostics segment as QuidelOrtho retrenches. Private equity firms like Carlyle Group and KKR, which have large healthcare portfolios, are the most likely acquirers, valuing the unit's infrastructure and intellectual property for a future consolidation play.
The primary risk to this thesis is a failed auction or a sale price deemed disappointing by the market. If the unit fetches a price below $500 million, it may not meaningfully improve QuidelOrtho's leverage ratio, leaving its balance sheet concerns unresolved. The market is pricing in a successful transaction, so a breakdown in talks could trigger another leg down in the stock. Analyst price targets for QDEL currently range from $15 to $28, reflecting high uncertainty.
Positioning data shows short interest in QDEL remains elevated near 12% of float, indicating significant skepticism about a near-term turnaround. Any positive news on the divestiture could force a short squeeze, creating volatile upward price action. Long-term institutional holders have been reducing their positions throughout 2025, transferring ownership to more speculative, event-driven funds.
The timeline for the sale process is the most critical near-term catalyst. Binding bids for the testing unit are expected by the end of the third quarter of 2026. QuidelOrtho's second-quarter earnings call, scheduled for early August, will provide management's first public commentary on the strategic review and updated financial guidance excluding the business.
Investors should monitor the company's debt covenants and credit rating. Moody's currently rates QuidelOrtho's corporate family rating at B1 with a negative outlook. A successful sale that generates significant cash proceeds could lead to a revision to stable. Key technical levels for the stock include solid support at the $15 level, a multi-year low, and resistance near $25, its 50-day moving average.
The outcome will also serve as a barometer for private equity appetite in the healthcare sector. A competitive bidding war would signal strong confidence in the long-term value of diagnostic infrastructure. A tepid response would suggest the market views pandemic-related assets as permanently impaired. For more on private equity trends, see our analysis of recent deals at Fazen Markets.
Retail investors who held through the downturn face a dilution of their investment thesis. The company is effectively abandoning the high-growth, high-volatility rapid test market to become a slower-growth clinical lab supplier. The sale's proceeds may be used to pay down debt rather than fund shareholder returns, limiting near-term upside. This event underscores the risks of investing in companies whose success is tied to a single, transient product cycle.
The situation mirrors Pfizer's 2025 decision to wind down its dedicated Covid-19 vaccine manufacturing network. Both cases involve scaling back infrastructure built for extraordinary demand that failed to materialize as endemic. However, QuidelOrtho's case is more acute because its entire corporate identity was reshaped by a merger during the boom, making the subsequent bust more structurally damaging to its balance sheet compared to a larger, more diversified pharmaceutical giant.
Vortex HFT is our free MT4/MT5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. Trades 24/5.
Position yourself for the macro moves discussed above
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.